← All trials
NCT05527704
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Sep 2, 2022
- Last posted
- Oct 10, 2022
- Enrollment
- 608
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical University of WarsawLead sponsor
- Jagiellonian UniversityCollaborator
- The Jan Biziel Hospital in BydgoszczCollaborator
- Pomeranian Medical UniversityCollaborator
- Poznan UniversityCollaborator
- University of OttawaCollaborator
- University of RzeszowCollaborator
- Medical University of WarsawOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.